Fig. 6: In vivo therapeutic efficacy of PGN_4.9 in different tumour models.

a Schematic illustration for 4T1-luciferase tumour immunotherapy. b Individual tumour growth kinetics and c average tumour growth curves of 4T1-luc tumour-bearing mice treated with PBS, free IMDQ, NPGN and PGN_4.9 (equivalent to 2 mg kg⁻¹ IMDQ, n = 7 mice). d Photographs and e weight of excised tumours (n = 7 mice, one-way ANOVA followed by Tukey’s multiple comparisons test). Scale bar, 2 cm. f Bioluminescence imaging and g corresponding quantification of lung metastases after intravenous administration (n = 7 mice, one-way ANOVA followed by Tukey’s multiple comparisons test). h Tumour immunotherapy after macrophage depletion in 4T1 tumour-bearing mice (n = 5 mice for combination group; n = 6 mice for other groups). i On day 7, BALB/c mice were inoculated subcutaneously with 4T1 cells. Tumour progression and j survival curves of 4T1 tumour-bearing mice treated with PGN_4.9 nanoadjuvant (equivalent to 1 mg kg⁻¹ IMDQ) and PDPA-DTX nanomedicine (equivalent to 3 mg kg⁻¹ DTX), alone or in combination on day 0, 4, 8 and 12 (n = 9 mice). k On day 73 and day 120, PGN_4.9 nanoadjuvant-treated mice in the MC38 colorectal tumour model were rechallenged with MC38 cells (2 × 10⁶ cells/mouse). For the control groups, naïve C57BL/6 mice were subcutaneously injected with the same number of MC38 cells (n = 9 mice at day 73 and n = 6 mice at day 120). l Schematic schedule of combined immunotherapy of α-PD1 and PGN_4.9. m Tumour progression and n survival curves of MC38 tumour-bearing mice treated with PBS, α-PD1 (100 μg per dose), PGN_4.9 nanoadjuvant (equivalent to 2 mg kg⁻¹ IMDQ) and combined administration (n = 11 mice for PBS group; n = 10 mice for other groups). The long-term survival was calculated by a log-rank test. Other statistical significance was analysed by two-way ANOVA followed by Tukey’s multiple comparisons test. All measurements are presented as mean ± s.d. Source data are provided as a Source Data file.